Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarechale Cap. Regulatory News (MAC)

Share Price Information for Marechale Cap. (MAC)

Share Price is delayed by 15 minutes
Get Live Data
7.60    1.05 (16.03%)
Bid:
7.20
Ask:
8.00
Spread: 0.80 (11.111%)
Market Cap: £9.08m
MAC Live PriceLast checked at - London Stock Exchange

Intraday Marechale Cap. Share Chart

Final Results

25 Jul 2014 10:13

RNS Number : 3463N
Marechale Capital PLC
25 July 2014
 



25 July 2014

 

 

Marechale Capital plc

("Marechale" of the "Company")

 

Consolidated Financial Statements for the year ended 31 March 2014

 

Marechale is pleased to announce its final results for the year ended 31 March 2014.

 

Financial highlights

Year ended 31 March

Change

2014

2013

£000

£000

Gross profit

518

470

+ 10%

Profit/loss before tax

79

(16)

-

Earnings/loss per share

0.14p

(0.03)p

-

Net assets

652

561

+ 16%

 

Business overview

· Deals completed in primary sectors of leisure/retail and renewable energy

· Northfield UK Solar currently completing second funding round

· Strong net gain in value of investments

 

Commenting, Mark Warde-Norbury, Chairman, said:

"Marechale has continued to build on the strong start to the year as reported in our interim statement. On the back of improving economic sentiment, and more confidence in the equity markets, we are pleased to report that we have made a profit of £79,000 (2013 loss £16,000) for the full year."

 

 

 

For further information please contact:

Marechale Capital

Tel: +44 (0)20 7628 5582

Mark Warde-Norbury

 

Patrick Booth-Clibborn

 

 

 

Smith & Williamson Corporate Finance

Tel: +44 (0)20 7131 4000

Dr Azhic Basirov

 

David Jones

 

 

 

Chairman's Statement

 

Marechale continued to build on the strong start to the year as reported in our interim statement. On the back of improving economic sentiment, and more confidence in the equity markets, the Company's Gross Profit - revenue less commissions paid to 3rd parties - has increased by 10% from £470,200 to £517,600. Furthermore, on the back of gains from our strategy of making investments in our client companies, we recorded 'Other Gains' (net) of £152,400 and we are pleased to report that we have made a profit of £80,000 (2013 loss £16,400) for the full year.

 

Marechale helps management teams to finance or refinance in two key areas of activity; Growth Capital through private equity transactions for more established businesses, and Development Capital, fundraising for smaller growth companies, the latter typically being Enterprise Investment Scheme (EIS) qualifying. As part of our success fee, the Company secures warrants or equity on most of its projects, so Marechale's shareholders have the opportunity to share in the potentially significant upside of the equity value in these businesses.

 

Marechale's core work is in the corporate finance advisory and capital raising activities for growth companies in two primary sectors in which the Marechale team has a long term track record -Leisure & Retail, and Renewable Energy.

 

During the year the Company completed a number of leisure deals, including the debt and equity funding raised for the North Eastern leisure group, Inn Collection. Further EIS funding has also been raised for the new brewhouse business, Brewhouse & Kitchen, and the Southern based managed pub group, Heartstone Inns. Most recently equity funding was completed for The Salt Yard restaurant group, further endorsing Marechale's strong position in funding businesses in the leisure sector. In the renewables sector funding has been raised for, amongst others, Future Biogas, the leading anaerobic digestion plant operator in the UK.

 

The Company's most significant initiative in the renewables sector is the development of ultra large scale solar energy sites in the UK, through Marechale's associated company, Northfield UK Solar Limited (Northfield). Established in 2013, Northfield is developing a portfolio of solar sites. This is one of the larger solar energy initiatives in the UK, and, whilst it is difficult to attribute values until planning permissions and grid connections for the various sites have been secured, there is significant potential uplift value for Marechale's shareholders from our investment in Northfield. Furthermore, Northfield is currently completing its second round of funding and Marechale's stake in Northfield at around 30% of the enlarged equity, is the Company's largest investment to date. The valuation on the balance sheet represents the first funding round, where the Company's investment, accounted for using the Equity Method was valued at £120,000, compared to cost of £500.

 

Details of other completed transactions on which the Company advised are all detailed on the Company's website at: www.marechalecapital.com.

 

Marechale remains committed to working with the management teams of quality companies to secure funding from the Company's extensive list of private and institutional investors.

 

There is an appetite amongst our investor contacts to invest in high quality investment opportunities. The Directors believe that backing the right growth companies, whilst not without its risks, represents an attractive private equity investment for investors looking to diversify their portfolios. Over the last three and half years, if an investor had invested in each of the 18 transactions Marechale has funded, based on the last round of funding or exit value of these transactions, we calculate that they would have achieved an IRR of over 23% to date.

 

Marechale is quoted on the London Stock Exchange as an AIM listed company and continues to look at a number of potentially interesting acquisitions, investment and merger opportunities, particularly in fund management, and remains open to such approaches. However, none has been progressed to date.

 

Mark Warde-Norbury

Chairman

24 July 2014

 

Consolidated Income Statement

Year ended 31 March 2014

 

Year ended

Year ended

31-Mar

31-Mar

Notes

2014

2013

(£)

(£)

Continuing operations

Revenue

2

752,818

590,993

Cost of sales

(235,234)

(120,808)

Gross profit

517,584

470,185

Administrative expenses

(590,611)

(574,046)

Operating (loss)

(73,027)

(103,861)

Investment revenues

1,734

-

Other gains

31,361

87,714

Exceptional gain on dilution of interest in associate

141,125

-

Net loss in respect of associate

(21,786)

-

Profit/ (loss) before tax

79,407

(16,147)

Taxation

-

(235)

Profit/ (loss) for the year on continuing operations

79,407

(16,382)

Profit/ (loss) per share

3

(Pence)

(Pence)

Basic

- Continuing operations

 £ 0.14

-0.03

 

Consolidated Statement of Comprehensive Income

 

Year ended

Year ended

31-Mar

31-Mar

2014

2013

(£)

(£)

Profit/ (loss) for the year

79,407

(16,382)

Other comprehensive income

Revaluation of investments

12,254

22,646

12,254

22,646

Total recognised comprehensive income

(all attributable to owners of the parent)

91,661

6,264

 

 

Consolidated Balance Sheet

Year ended 31 March 2014

 

Year ended

Year ended

31-Mar

31-Mar

2014

2013

(£)

(£)

Non current assets

Investment in associate

119,845

-

Current assets

Available for sale investments

108,417

124,383

Trading investments

77,125

67,555

Trade and other receivables

221,003

193,536

Cash and cash equivalents

275,268

262,218

681,813

647,692

Total assets

801,658

647,692

Current liabilities

Trade and other payables

(149,319)

(87,014)

Total current liabilities

(149,319)

(87,014)

Net assets

652,339

560,678

Equity

Capital and reserves attributable to equity shareholders

Share capital

2,474,308

2,474,308

Share premium account

1,247,379

1,247,379

Revaluation reserve

51,889

39,635

Reserve for own shares

(50,254)

(50,254)

Retained losses

(3,070,983)

(3,150,390)

652,339

560,678

 

 

Statement of Changes in Equity

Year ended 31 March 2014

 

Share capital

Share premium

Revaluation reserve

Reserve for own shares

Retained earnings

Group

(£)

(£)

(£)

(£)

(£)

Balance at 31 March 2012

2,421,870

1,227,453

16,989

(50,254)

(3,134,008)

Issue of ordinary share capital

52,438

19,926

-

-

-

Release of reserve for lapsed options

-

-

-

-

-

Transactions with owners

52,438

19,926

-

-

-

Total comprehensive income

Loss for the financial year

-

-

-

-

(16,382)

Revaluation during the financial year

-

-

22,646

-

-

Total comprehensive income

-

-

22,646

-

(16,382)

Balance at 31 March 2013

2,474,308

1,247,379

39,635

(50,254)

(3,150,390)

Issue of ordinary share capital

-

-

-

-

-

Release of reserve for lapsed options

-

-

-

-

-

Transactions with owners

0

0

-

-

-

Total comprehensive income

Profit for the financial year

-

-

-

-

79,407

Revaluation during the financial year

-

-

12,254

-

-

Total comprehensive income

-

-

12,254

-

79,407

Balance at 31 March 2014

2,474,308

1,247,379

51,889

(50,254)

(3,070,983)

 

Movements of the Revaluation reserve consist of:

2014

2013

Unrealised gains

12,254

22,646

Release of unrealised gains to Profit and Loss

-

-

12,254

22,646

Reserves for own shares consists of:

Reserve for employee share ownership plan ('ESOP')

(50,254)

(50,254)

Reserve for share based payments

-

-

(50,254)

(50,254)

 

The Reserve for ESOP comprises 232,603 shares in the Group held in an ESOP Trust. As at 31 March 2014 and 2013, none of the shares had been unconditionally granted to any of the Group's employees and had an aggregate market value of £4,652 (2013: £2,719).

 

 

Consolidated Cash Flow Statement

Year ended 31 March 2014

 

Year ended

Year ended

31-Mar

31-Mar

2014

2013

(£)

(£)

Net cash from operating activities

Continuing operations: Operating loss

(73,027)

(103,861)

Operating cash flows before movements in working capital

(73,027)

(103,861)

Movement in working capital

(Increase) in receivables

(28,438)

(40,471)

Increase in payables

63,275

31,413

Tax paid

-

(235)

34,837

(9,293)

Operating cash flow

(38,190)

(113,154)

Investment activities

Interest receivable

1,734

-

Proceeds on disposal of trading investments

44,807

24,258

Proceeds on disposal of available for sale investments

5,205

3,500

Expenditure on available for sale investments

(506)

(35,500)

Cash flow from investing activities

51,240

(7,742)

Financing

Issue of share capital

-

72,364

Cash flow from financing activities

0

72,364

Net increase/ (decrease) in cash

and cash equivalents

13,050

(48,532)

Cash and cash equivalents at start of the financial year

262,218

310,750

Cash and cash equivalents at end of the financial year

275,268

262,218

Increase/ (decrease) in cash and cash equivalents

13,050

(48,532)

 

 

Notes to the Financial Information

Year ended 31 March 2014

 

1. Basis of preparation

These financial statements have been prepared in accordance with International Financial Reporting Standards ('IFRS') as adopted by the European Union and the International Financial Reporting Interpretations Committee ('IFRIC') interpretations in accordance with the Companies Act 2006. The financial statements have been prepared on the historical cost basis as modified by the valuation of certain financial instruments.

 

The principal accounting policies adopted in the preparation of the financial information is this announcement are set out in the Company's full financial statements for the year ended 31 March 2014.

 

2. Business and geographical segments

The directors consider that there is only one activity undertaken by the Group, that of corporate finance advisory. All of this activity was undertaken in the United Kingdom.

 

2014

2013

(£)

(£)

Broking commissions and fees earned from corporate finance

752,818

590,993

 

3. Earnings per share

 

Earnings

Earnings

(£)

(£)

Based on a profit/ (loss) of

79,407

(16,382)

No. shares

No. shares

Weighted average number of Ordinary Shares in issue

57,681,151

53,748,345

for the purpose of basic earnings per share

 

4. Other matters

The financial information for the year ended 31 March 2014 set out in this announcement does not constitute statutory financial statement, as defined in section 434 of the Companies Act 2006, but is based on the statutory financial statements for the year then ended. Those financial statements, upon which the auditors have issued an unqualified opinion, will be delivered to the Registrar of Companies.

 

Copies of the Company's full audited Annual Report and Financial Statements for the year ended 31 March 2014 will be sent to shareholders in due course and will be available on the Company's website: www.marechalecapital.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR RAMLTMBMTMLI
Date   Source Headline
8th Jun 20267:00 amPRNFCA Approves Stanford Capital Partners Change in Control
3rd Jun 20267:00 amPRNPosting of Circular and Notice of General Meeting
10th Apr 20261:00 pmPRNWeardale Lithium Receives £700k Grant
19th Jan 202612:15 pmPRNHalf-year Report
14th Oct 20254:00 pmPRNResult of AGM
14th Oct 20257:00 amPRNSubscription, Directors' Dealings, Related Party Transaction and Issue of Equity
16th Sep 20259:30 amPRNNotice of AGM
22nd Aug 20257:00 amPRNFinal Results
13th May 20257:00 amPRNIssue of Options to PDMR
19th Mar 20257:00 amPRNMarechale Advises on the Sale of Randalls
5th Feb 20251:30 pmPRNWeardale Lithium Planning Permission Application Update
29th Jan 202511:37 amPRNShare Price Movement
19th Dec 20244:30 pmPRNHalf-year Report
15th Oct 20242:30 pmPRNResult of AGM
20th Sep 20247:00 amPRNNotice of AGM
20th Aug 20247:00 amPRNFinal Results
6th Aug 20247:00 amPRNAppointment of Director
5th Dec 20237:00 amPRNHalf-year Report
22nd Nov 20231:00 pmPRNDirectorate Change
13th Oct 20233:51 pmPRNResult of AGM
19th Sep 20233:40 pmPRNNotice of AGM and Posting of Accounts
22nd Aug 20237:00 amPRNFinancial Statements for the Year Ended 30 April 2023
3rd Aug 202312:00 pmPRNHolding(s) in Company
28th Jun 20237:00 amPRNSubscription and Issue of Equity
2nd Mar 20227:00 amPRNPlacing, Subscription and Issue of Equity
1st Dec 20217:00 amPRNHalf-year Report
14th Oct 20213:28 pmRNSResult of AGM
11th Oct 20213:08 pmPRNHolding(s) in Company
8th Oct 20213:29 pmPRNHolding(s) in Company
5th Oct 20217:00 amPRNSubscription and Issue of Equity
22nd Sep 20212:57 pmPRNNotice of AGM
8th Sep 202111:54 amPRNHolding(s) in Company
7th Sep 20212:11 pmPRNDirector/PDMR Shareholding
23rd Aug 20217:00 amRNSFinal Results
12th Mar 20219:32 amPRNHolding(s) in Company
5th Mar 20211:29 pmPRNHolding(s) in Company
5th Mar 20218:50 amPRNHolding(s) in Company
4th Mar 20213:24 pmPRNTrading Update
4th Mar 20219:19 amPRNHolding(s) in Company
23rd Feb 20215:00 pmPRNHolding(s) in Company
23rd Feb 20217:00 amPRNDirector/PDMR Shareholding
10th Feb 20212:27 pmPRNHolding(s) in Company
10th Feb 20217:00 amPRNHolding(s) in Company
4th Feb 20219:15 amPRNExercise of Options and Issue of Equity
3rd Feb 20217:00 amPRNStatement re Share Price Movement
2nd Feb 20216:20 pmPRNHolding(s) in Company
26th Jan 202111:47 amPRNPlacing, Subscription and Issue of Equity
11th Dec 202012:47 pmPRNGrant of Options to Directors
24th Nov 20207:00 amPRNHalf-year Report
26th Oct 20201:16 pmPRNResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.